BioSante Pharmaceuticals to Ring NASDAQ Closing Bell

CEO to present at Flaherty Financial Small Cap Conference
LINCOLNSHIRE, Ill.--(Business Wire)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that
Dr. Louis W. Sullivan, its chairman, and Stephen M. Simes, its chief
executive officer, will ring the closing bell at the NASDAQ site in
Times Square on Thursday January 17, 2008. The bell ringing is in
honor of BioSante's recent move of its listing to the NASDAQ Stock
Market.

"Closing the NASDAQ is a tremendous honor and an opportunity to
commemorate our new NASDAQ listing," said Simes, of the event.

In addition, BioSante announced that Mr., Simes, will present a
corporate update and overview at the Flaherty Financial/Wall Street
Research Small Cap Conference, in New York City. Mr. Simes will
present on January 22, 2008 at 12:00 p.m. local time. The Flaherty
Conference will feature companies presenting to a diverse group of
investors, portfolio managers and analysts interested in the
biotechnology and pharmaceuticals sectors.

A live audio webcast of BioSante's presentation at the Flaherty
Conference may be accessed at
http://www.biosantepharma.com/investors/events.html and a replay will
be available at the same link for 60 days.

About NASDAQ

NASDAQ(R) is the largest U.S. electronic stock market. With
approximately 3,100 companies, it lists more companies and, on
average, its systems trade more shares per day than any other U.S.
market. NASDAQ is home to companies that are leaders across all areas
of business including technology, retail, communications, financial
services, transportation, media and biotechnology. NASDAQ is the
primary market for trading NASDAQ-listed stocks. For more information
about NASDAQ, visit the NASDAQ website at http://www.nasdaq.com or the
NASDAQ Newsroom(SM) at http://www.nasdaq.com/newsroom

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver estradiol and
testosterone. BioSante's lead products include LibiGel(R) (transdermal
testosterone gel) in Phase III clinical development by BioSante for
the treatment of female sexual dysfunction (FSD) and Elestrin(TM)
(estradiol gel) developed through U.S. Food and Drug Administration
(FDA) approval by BioSante indicated for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's
licensee. Also in development are Bio-T-Gel(TM), a testosterone gel
for male hypogonadism, and an oral contraceptive in Phase II clinical
development using BioSante patented technology. The current market in
the U.S. for estrogen and testosterone products is approximately $2.5
billion and for oral contraceptives approximately $3.0 billion. The
company also is developing its calcium phosphate nanotechnology (CaP)
for novel vaccines, drug delivery, and aesthetic medicine
(BioLook(TM)). Additional information is available online at:
www.biosantepharma.com.

McKinney/Chicago
Alan Zachary, (312) 944-6784 ext. 316
azachary@mckinneychicago.com
www.mckinneychicago.com

Copyright Business Wire 2008